

EXHIBIT A
CLAIMS UPON ENTRY OF THE AMENDMENT

1. (Twice amended) An antibody or antigen binding fragment thereof which is specifically reactive with a polypeptide or an antigen fragment thereof, wherein the polypeptide is characterized as:

- a) having an amino acid sequence corresponding to the carboxy terminal amino acids of a connective tissue growth factor (CTGF) protein;
- b) binding to heparin and being eluted from heparin with about 0.8 M salt; and
- c) having a molecular weight of about 10 kDa to about 20k Da by reducing SDS-PAGE,

wherein the polypeptide has an amino acid sequence beginning at about amino acid residue 247 or amino acid residue 248 from the N-terminus of CTGF, and has mitogenic and chemotactic activity, and

wherein the antibody or antigen binding fragment thereof is not reactive with CTGF or with platelet derived growth factor.

- 2. The antibody of claim 1, wherein the antibody is polyclonal.
- 3. The antibody of claim 1, wherein the antibody is monoclonal.
- 4. The antibody of claim 1, wherein the antibody is a human antibody.
- 5. The antibody of claim 1, wherein the antibody is a single chain antibody.
- 6. The antibody of claim 1, wherein the antibody is a humanized antibody.

In re Application of
Brigstock and Harding
Application No.: 09/113,924
Filed: July 9, 1998
Exhibit A - Page 2

PATENT
Attorney Docket No.: FIBRO1120-1
(08766/003002)

7. (Amended) The antigen binding fragment of claim 1, wherein the antigen binding fragment is an antibody fragment.